2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5335 Fixed-duration subcutaneous mosunetuzumab in patients with previously untreated high-tumor burden follicular lymphoma: Two-year follow-up analysis and patient-reported outcomes of the MorningSun Phase II study

L. Elizabeth Elizabeth Budde, MD PhD, John M. Burke, MD2, Jeff Sharman, MD3, Bertrand Anz, MD4, Richard Zuniga5, Aung M. Tun, MD6, Juliana M. L. Biondo7, Mei Wu, PharmD8, Farah Hossain9, Yong Mun, PhD10, Avrita Singh, MPH11, Rona Farighi, PharmD12, Jose C Villasboas, MD13, Ian W. Flinn, MD, PhD14
1 City of Hope National Medical Center, Duarte, California, United States
2 Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Aurora, Colorado, United States
3 Willamette Valley Cancer Institute, Sarah Cannon Research, Eugene, OR, United States
4 Tennessee Oncology, Chattanooga, Tennessee, United States
5 New York Cancer & Blood Specialists, Port Jefferson, New York, United States
6 The University of Kansas Cancer Center, Kansas City, Kansas, United States
7 Genentech, Inc., South San Francisco, California, United States
8 Genentech, Inc., South San Francisco, California, United States
9 Genentech, Inc., South San Francisco, California, United States
10 Genentech, Inc., South San Francisco, California, United States
11 Genentech, Inc., South San Francisco, California, United States
12 Genentech, Inc., South San Francisco, California, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Tennessee Oncology and OneOncology, Nashville, Tennessee, United States

Background: Mosunetuzumab is a fixed-duration CD20×CD3 bispecific antibody approved for relapsed/refractory follicular lymphoma (FL) after ≥2 prior lines of therapy and can be administered in an outpatient setting. In the Phase II MorningSun study (NCT05207670), subcutaneous (SC) mosunetuzumab demonstrated promising efficacy and manageable safety at the 22-month follow-up in a cohort of patients (pts) with previously untreated high-tumor burden (HTB) FL; circulating tumor DNA analysis in a subset of pts with complete metabolic response (CMR) showed that 84.2% were minimal residual disease-negative at Cycle (C)4 (Burke et al. ASH 2025). We report 2-year follow-up and patient-reported outcomes (PROs) of mosunetuzumab SC in this cohort of pts with previously untreated HTB FL.

Methods: Pts with previously untreated HTB FL (Groupe D’Etude des Lymphomes Folliculaires criteria) and Eastern Cooperative Oncology Group performance status of 0–2 were enrolled. Mosunetuzumab SC was administered with step-up dosing: C1 (Day [D]1, 5mg; D8, 45mg; D15, 45mg) followed by 45mg on D1 of each 21-day cycle for up to 17 cycles (1 year). Pts with a partial metabolic response or CMR after C17 could receive optional mosunetuzumab maintenance (45mg every 8 weeks for ≤1 year). Hospitalization was not required. The primary endpoint was progression-free survival (PFS) rate at 2 years. Key secondary endpoints were objective response rate (ORR), overall survival (OS), duration of response (DOR), duration of complete response (DOCR) and safety. PROs were assessed as change from baseline (CfB) in lymphoma symptoms (LS) using the lymphoma-specific subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LYMS; range: 0–60; higher scores indicate improvement; ≥3-point gains are considered clinically meaningful).

Results: As of February 2, 2026, 103 pts were enrolled (US community sites, n=82; academic sites, n=21). Median age was 65 years (range: 24–86) and 51.5% of pts were female; most pts had Ann Arbor stage III/IV disease (91.3%) and a FLIPI score ≥2 (78.6%). In total, 70 pts completed initial treatment (17 cycles) and 33 discontinued (mainly due to progressive disease [PD; n=18] and adverse events [AEs; n=5]). Of 70 pts eligible for maintenance therapy, 47 received maintenance, of whom 31 completed treatment and 16 discontinued (mainly due to PD [n=7] and AEs [n=3]).

After a median follow-up of 30.6 months (95% confidence interval [CI]: 29.5–32.7), 2-year PFS was 61.3% (95% CI: 50.5–70.4), median PFS was 33.8 months (95% CI: 24.9–not estimable [NE]). The ORR was 88.3% (95% CI: 80.5–93.8), with a CMR of 67.0%. Two-year OS, DOR, and DOCR rates were 89.8% (95% CI: 81.9–94.4), 64.6% (95% CI: 53.1–74.0) and 70.4% (95% CI: 56.9–80.3), respectively.

In pts who received maintenance (n=47), 2-year PFS was 76.5% (95% CI: 60.7–86.6), median PFS was 37.1 months (95% CI: 33.8–NE). The ORR was 100% (95% CI: 92.5–100), with a CMR of 76.6%. Two-year OS, DOR, and DOCR rates were 95.6% (95% CI: 83.4–98.9), 76.5% (95% CI: 60.7–86.6) and 79.0% (95% CI: 59.0–90.0), respectively. Overall, the most common AEs (≥30%) were injection-site reaction (67.0%), fatigue (45.6%), cytokine release syndrome (CRS; 34.0%), headache (32.0%) and nausea (32.0%). Grade (Gr) ≥3 and serious AEs were reported in 49.5% and 37.9% of pts, respectively. Five pts had Gr 5 AEs: COVID-19 pneumonia (n=2) and cardiogenic shock, unexplained death, pneumonia (n=1 each). Infections occurred in 78.6% of pts and were predominantly Gr 1/2 (59.2%; Gr ≥3, 19.4%); the most common infection was COVID-19 (24.3%). During maintenance (n=47), Gr ≥3 and serious AEs occurred in 51.1% and 31.9% of pts, respectively; infections occurred in 48.9% of pts and no CRS events were reported. FACT-Lym LYMS completion rates were high: 98.1% at baseline, ≥87.8% at subsequent timepoints and 92.5% during maintenance. Baseline LS were low with a mean score of 46.7 (standard deviation [SD], 9.9) and mean CfB scores improved over time: C4D1, 2.2 (SD, 7.1); C9D1, 4.2 (SD, 7.3); C17D1, 4.2 (SD, 8.6); C20D1 maintenance, 3.5 (SD, 9.0) with clinically meaningful improvements observed at C9D1, C17D1 and C20D1.

Conclusion: With >2-years of follow-up, fixed-duration outpatient mosunetuzumab SC with optional maintenance provided durable efficacy and manageable safety as a first-line treatment for HTB FL. Improvements in LS support a positive impact of mosunetuzumab SC on health-related quality of life in this population.

L. Elizabeth Elizabeth Budde, MD PhD: Genentech, Inc., BMS, AstraZeneca, Crispr Therapeutics, ADC Therapeutics, Kite Pharma - Honoraria; AstraZeneca, Merck - Research Funding